Global Mastitis Market: Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), by Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), by End User (Veterinary Centers and Hospital & Clinics) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2023

The Global Mastitis Market is expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow’s udder.

The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.

Market Dynamics

Mastitis has been gaining significance in recent years, owing to the rising incidence of breast cancer. For instance, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018 in the US. Similarly, the UK witnessed around 11,563 deaths due to breast cancer in 2016, according to the Cancer Research UK. Whereas, according to the World Cancer Research Fund International, Belgium had the highest rate of breast cancer in women in 2017. Such a vast population suffering from breast cancer boosts market growth during the forecast period.
Segmentation

The global mastitis market, by type, has been segmented into bovine and human. Based on treatment, the Mastitis market has been categorized as bovine and human. Based on end user, the mastitis market has been classified as veterinary centers and hospital & clinics.

Asia-Pacific Mastitis Market Share, 2016 (%)

Regional Analysis

The global mastitis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global mastitis market. North America is expected to dominate the market, mainly due to the increasing prevalence of mastitis among the bovine population and increasing incidence of breast cancer in the region.

Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are advanced treatment facilities, rising
government initiatives to promote healthy breastfeeding, and growing healthcare expenditure. For instance, according to Eurostat, Germany spent over EUR 321 billion in 2014.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea. Moreover, the vast patient pool of chronic diseases and government initiatives of healthcare reforms will support the growth of the market.

The mastitis market in the Middle East & Africa is expected to grow due to the affordability and accessibility of healthcare.

Key Players

The prominent players in the global Mastitis market are Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apheria Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).

Some of the key strategies followed by players operating in the global mastitis market were innovation, product development, and acquisition & mergers.

- In June 2018, Boehringer Ingelheim announced a 230-million-euro investment in a new Biological Development Centre (BDC) at the company’s research development sites in Biberach Germany.

- In June 2017, BioNumerik Pharmaceuticals received approval for Tavocept as an investigational new drug with potential for oncology and non-oncology indications.

- In May 2017, Merck Co. & received FDA approved Keytruda for the treatment of adult and pediatric patients with previously treated unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient, solid tumors.

Market Segmentation

Global Mastitis Market, by Type

- Bovine
  - Contagious Mastitis
  - Environmental Mastitis
  - Opportunist Mastitis
- Human
  - Non-Infectious Mastitis
  - Infectious Mastitis

Global Mastitis Market, by Treatment

- Bovine
  - Antibiotics
  - Vaccines
- Human
  - Pain Relievers
  - Antibiotics

Global Mastitis Market, by End User

- Veterinary Centers
- Hospital & Clinics

Global Mastitis Market, by Region

- Americas
  - North America
    - US
    - Canada
  - Latin America
- Europe
- Western Europe
  - Germany
  - UK
  - France
  - Italy
  - Spain
  - Rest of Western Europe
- Eastern Europe
- Asia-Pacific
  - China
  - Japan
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
- Middle East & Africa
  - Saudi Arabia
  - United Arab Emirates
  - Kuwait
  - Oman
  - Qatar
  - Rest of Middle East

Available Additional Customizations
- Company Profiles of Other Key Players
  - HIPRA
  - Others
- Mastitis Market, Industry Trends

Intended Audience
- Pharmaceutical Companies
- Research & Development Organizations
- Veterinary Institutes
Infographic Summary:

Contents:

**GLOBAL MASTITIS MARKET**

The global mastitis market is expected to reach USD 18,338.80 million by 2023.

**Global Mastitis Market Share, by Region, 2016**

DRIVERS:
- Rising cases of breast cancer
- Increasing rate of pregnancy
- Unhygienic barn conditions causing contagious mastitis in bovines

RESTRAINT:
- Lack of awareness
- Complications in diagnosis due to similar symptoms of breast cancer & mastitis

KEY PLAYERS:
- Zoetis Inc.
- Merck Co. & Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bayer Animal Health

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

2.1 Definition 19
2.2 Scope of the Study 19
2.3 Research Objective 19
2.4 Assumptions & Limitations 19
2.4.1 Assumptions 19
2.4.2 Limitations 19